Cargando…

Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy

Patient: Female, 47-year-old Final Diagnosis: Idiopathic thrombocytopenia Symptoms: Bruising • diarhea • thrombocytopenia Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: First-line treatments for patients with immune thromboc...

Descripción completa

Detalles Bibliográficos
Autor principal:	Maitland, Hillary S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656289/ https://www.ncbi.nlm.nih.gov/pubmed/34862358 http://dx.doi.org/10.12659/AJCR.933788

Ejemplares similares

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
por: Oladapo, Abiola, et al.
Publicado: (2023)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
por: Abdelsamia, Mahmoud, et al.
Publicado: (2023)

Correction to: Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022)

Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation
por: Zhou, Meng, et al.
Publicado: (2022)

Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
por: Mladsi, Deirdre, et al.
Publicado: (2020)

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China
por: Mei, Heng, et al.
Publicado: (2023)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
por: Barak, Avital F., et al.
Publicado: (2011)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis
por: Wojciechowski, Piotr, et al.
Publicado: (2021)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
por: Aiello, Andrea, et al.
Publicado: (2023)

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012)

Sialic acid and platelet count regulation: Implications in immune thrombocytopenia
por: Lee‐Sundlov, Melissa M., et al.
Publicado: (2022)

Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
por: Huang, Ao, et al.
Publicado: (2022)

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure
por: Satapathy, Sanjaya K., et al.
Publicado: (2023)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies
por: Poordad, Fred, et al.
Publicado: (2020)

P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023)

Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization
por: Lim, Ming Y., et al.
Publicado: (2020)

Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia
por: Li, Na, et al.
Publicado: (2021)

Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia
por: Lee, Ayoung, et al.
Publicado: (2020)

Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count
por: Page, David, et al.
Publicado: (2021)

Reticulated Platelet Count as a Diagnostic Tool in Immune Thrombocytopenia (ITP)
por: Butt, Aqsa Javed, et al.
Publicado: (2023)

Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Chunlu, et al.
Publicado: (2019)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis
por: Lu, Jun, et al.
Publicado: (2022)

Laparoscopic splenectomy for immune thrombocytopenia in patients with a very low platelet count
por: Zychowicz, Anna, et al.
Publicado: (2018)

Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia
por: Grodzielski, Matías, et al.
Publicado: (2019)

Platelet count as an important prognostic factor for vaccine-induced immune thrombotic thrombocytopenia
por: Bang, Soo-Mee, et al.
Publicado: (2021)

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Zhu, Lidan, et al.
Publicado: (2022)

Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study
por: Ruan, Yongsheng, et al.
Publicado: (2023)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias
por: Bury, Loredana, et al.
Publicado: (2021)

Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia
por: Tu, Xiaofang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1p5k5lep8bpup4ib7ec0tmuai9